Inhibidores de ALK: progresos terapéuticos - page 34

Current treatment strategy for metastatic

ALK

+ NSCLC

Current

strategy

2nd generation

ALK TKI

Crizotinib

Lorlatinib

Potential

future

strategy

Lorlatinib

2nd generation ALK TKI

INDICACIÓN NO APROBADA, EN INVESTIGACIÓN

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,24,25,26,27,28,29,30,31,32,33 35,36,37,38,39,40,41,42,43,44,...48